SAN JOSE, Calif.--(BUSINESS WIRE)--Evident Vascular, Inc., a medical technology startup backed by Vensana Capital® developing an AI-powered next-generation intravascular ultrasound (IVUS) platform, is pleased to announce the appointment of Scott R. Ward to its Board of Directors.
With over 40 years of leadership in healthcare and medical technology, Mr. Ward most recently held key roles, including CEO and Chairman of Cardiovascular Systems, Inc. before its acquisition by Abbott, and nearly 30 years at Medtronic, where he led the Cardiovascular, Neurological, and Diabetes businesses, driving transformative growth. Beyond his executive career, Mr. Ward has served on over 15 public and private company boards, chairs the Philanthropy Board at Gillette Children’s Hospital, and founded Raymond Holdings, a venture capital and advisory firm for MedTech and life sciences.
“We are thrilled to welcome Scott to the Evident Vascular Board,” said Howard Rosen, CEO of Evident Vascular. “Scott’s extensive experience and strategic vision will be instrumental as we continue to advance our AI-powered IVUS platform to improve clinical outcomes and expand adoption across peripheral and coronary vascular interventions.”
Mr. Ward’s appointment reflects Evident Vascular’s commitment to assembling a team of visionary leaders to guide its strategic direction. His expertise aligns with the company’s focus on introducing a next-generation IVUS platform that addresses critical needs in the vascular imaging space.
“I am honored to join the Evident Vascular Board during this pivotal and exciting phase of the company's journey,” said Scott R. Ward. “Evident’s innovative IVUS platform has the potential to redefine image guided therapy and significantly improve patient care. I look forward to contributing to the company’s growth and success.”
About Evident Vascular
Evident Vascular, Inc., is developing an advanced intravascular ultrasound (IVUS) platform technology designed initially for peripheral vascular interventions, with future capability for coronary procedures. Leveraging artificial intelligence (AI) to enable superior image interpretation and streamlined workflows, Evident Vascular’s technology has been designed to expand adoption of IVUS, driving increased market penetration and enabling improved clinical outcomes with faster, more accurate diagnosis and treatment decisions. For more information, visit the company’s website and follow us on LinkedIn.
Evident Vascular™ and Evident™ are trademarks of Evident Vascular, Inc.
Vensana Capital® is a registered trademark of Vensana Capital Management, LLC.
This press release contains “forward-looking statements” concerning the development of Evident Vascular’s products, the benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Evident Vascular undertakes no obligation to update any forward-looking statements for any reason.
